Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 253

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 253
---
 conference. Mr. Hwang began by explaining that currently, BLAC was considering an affiliated transaction with OSR Holdings, that OSR Holdings was considering acquiring additional portfolio companies, and that any acquisition of Company C would have to be via acquisition by OSR Holdings. Company C’s Chief Business Officer said Company C was only considering a direct business combination with a SPAC. There were no further communications with Company C. Company D Another potential target company (“Company D”) was introduced to former OSR Holdings Managing Director Sung Hoon Chung’s former colleague at Auerbach Grayson (“Broker”) on March 23, 2023. Company D is a clinical stage biotech company with a pipeline of three clinical trials on Glioblastoma Multifore (“GBM”). On March 23, 2023, Broker circulated a non -confidentialcompany presentation to BLAC for review. Further emails were exchanged between BLAC/OSR Holdings and Broker to arrange a meeting in Korea with Company D and a Korean biopharma company with a controlling stake in Company D (“Parent D”). Mr. Whang met with Broker in New York City on April 12, 2023 to further discuss Company D and BLAC’s business combination strategy. 149 By way of further background, Parent D was formerly in the lifesaving boat business. Parent D acquired an American lifeboat company in the U.S. in 2009, and until then, had no prior involvement or business interest in the biotech space. For reasons unknown to BLAC, the US company acquired by Parent D held a controlling stake in an early -stagebiotech. Post -takeover, Parent D management took an active interest in the acquired biotech investment and determined the company presented significant business opportunities, which led to the launch of Parent D specifically in the Korean biotech space. After 14 years of drug development progress, earlier in 2023, the acquired biotech company submitted a New Drug Application to the US Food and Drug Administration for its investigational drug, rivoceranib, for use in combination with an approved drug, camrelizumab, in China for unresectable hepatocellular carcinoma. Subsequent to its acquisition of Company D, Parent D transformed into one of the most visible biopharma groups in Korea. Subsequent to Mr. Whang’s meeting with Mr. Shin, on or about July 3, 2023, the newly -appointedCFO of Parent D requested a meeting with OSR Holdings as